<DOC>
	<DOC>NCT01148953</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-TTR01 in patients with transthyretin (TTR) mediated amyloidosis (ATTR).</brief_summary>
	<brief_title>Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Diagnosis of TTR amyloidosis Adequate blood counts, liver and renal function Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must use an adequate method of birth control Males agree to use appropriate contraception Willing and able to comply with protocolrequired visit schedule and visit requirements and provide written informed consent. Known human immunodeficiency virus (HIV) positive status Receiving antibiotics for bacterial infection within 7 days of screening Known or suspected systemic viral, parasitic or fungal infection Receiving an investigational agent within 30 days prior to study drug administration Poor cardiac function Considered unfit for the study by the Principal Investigator Known sensitivity to oligonucleotides Employee or family member of the sponsor or the clinical study site personnel.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>